⌘K
Loading ticker…
As of 2026-08-24, Coherus Oncology, Inc. Common Stock (CHRS) has a 3-month relative strength percentile of 24 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 48. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 7.8%, relative volume 0.85×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
CHRS is held by 16 ETFs as of May 2026. Top owner: SCHA at 0.00% weight, $1M notional. Top 3 carry $2M.
Held by 27 ETFs · $18M across latest filings · largest weight 0.62% (SURI).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| SCHASchwab U.S. Small-Cap ETF | 0.00% | $1M | — |
| VTWO | 0.00% | $851K | — |
| SCHBSchwab U.S. Broad Market ETF | 0.00% | $146K | — |
| VTWV | 0.01% | $87K | — |
| QQQS | 0.39% | $73K | −0.19 pp |
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Related searches
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.00% |
| $52K |
| — |
| AVSC | 0.00% | $22K | — |
| IBBQ | 0.02% | $13K | — |
| VTHRVanguard Russell 3000 ETF | 0.00% | $11K | — |
| BIB | 0.01% | $9K | — |
Showing 10 of 16 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CHRS Jan avg: 2.31% median: -3.71% win: 50% σ: 37.46% n: 4 2022-04-12 → 2026-07-31 | CHRS Feb avg: -10.68% median: -13.05% win: 25% σ: 13.37% n: 4 2022-04-12 → 2026-07-31 | CHRS Mar avg: -5.06% median: 1.12% win: 75% σ: 14.93% n: 4 2022-04-12 → 2026-07-31 | CHRS Apr avg: -1.06% median: 5.03% win: 60% σ: 21.20% n: 5 2022-04-12 → 2026-07-31 | CHRS May avg: -20.83% median: -18.80% win: 0% σ: 14.34% n: 5 2022-04-12 → 2026-07-31 | CHRS Jun avg: -4.00% median: -4.95% win: 20% σ: 6.04% n: 5 2022-04-12 → 2026-07-31 | CHRS Jul avg: 9.63% median: 12.88% win: 80% σ: 15.23% n: 5 2022-04-12 → 2026-07-31 | CHRS Aug avg: 14.05% median: 16.98% win: 75% σ: 18.14% n: 4 2022-04-12 → 2026-07-31 (current) | CHRS Sep avg: -6.92% median: -19.61% win: 25% σ: 32.87% n: 4 2022-04-12 → 2026-07-31 | CHRS Oct avg: -11.46% median: -9.95% win: 25% σ: 12.70% n: 4 2022-04-12 → 2026-07-31 | CHRS Nov avg: -3.21% median: -20.10% win: 25% σ: 45.31% n: 4 2022-04-12 → 2026-07-31 | CHRS Dec avg: 22.33% median: 14.28% win: 100% σ: 23.16% n: 4 2022-04-12 → 2026-07-31 |